Pharmaceutical News

RSS

Having lower TSH levels while taking thyroxine replacement is not detrimental to health, says study

New research shows that it may be safe for patients taking thyroxine replacement to have low but not suppressed thyroid stimulating hormone (TSH) levels. The research, presented at the Society for Endocrinology BES meeting in Manchester, shows for the first time that it may be safe for patients to take slightly higher doses of thyroxine than are currently recommended.

18 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct.

18 Mar 2010

Acurox NDA: FDA schedules Advisory Committee meeting

Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.

18 Mar 2010

Nature News examines GAVI Alliance's budget gap

Nature News examines GAVI Alliance's multi-billion-dollar budget shortfall ahead of a donors meeting in The Hague on March 25-26.

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

Actavis receives FDA marketing approval for Alprazolam ODT

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.

18 Mar 2010

Hypnotherapy and probiotics effective for reducing IBS symptoms

Hypnotherapy seems to be very effective for easing the distressing symptoms of irritable bowel syndrome (IBS), and in a goodly proportion of cases, clears up symptoms altogether, reveal experts during a wide ranging discussion of the condition in a Frontline Gastroenterology podcast.

18 Mar 2010

NICE leaves many patients with rarer forms of cancer without drugs

The National Institute for Health and Clinical Excellence (NICE) is failing to follow its own guidance aimed at making live-extending treatments available on the NHS, leaving many patients with rarer forms of cancer without drugs that could prolong their lives, a campaign group has said.

18 Mar 2010

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

The role of selenium in diabetes has been controversial, with some studies suggesting that it raises diabetes risk and others finding that it is protective. Now, research published in BioMed Central's open access journal Nutrition and Metabolism, has shown that, for men, high plasma selenium concentrations are associated with a lower occurrence of dysglycemia.

18 Mar 2010

Purified form of omega 3 curbs precancerous bowel polyps

A purified form of an omega 3 cuts the number and size of precancerous bowel growths (polyps) in people whose genetic make-up predisposes them to bowel cancer, finds research published ahead of print in the journal Gut.

18 Mar 2010

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Executives from pharmaceutical companies and health care payer and provider organizations convened at the "Selling Pharmaceuticals in 2015" forum in Philadelphia to discuss mutually beneficial partnerships that, if implemented, could replace the traditional model of selling drugs on price, features and benefits with a new model that focuses on quantifying and communicating total value.

18 Mar 2010

Drugmakers are 'under-exposed' in emerging markets, report says

Growing markets for pharmaceuticals in China, Brazil, Russia and India are outpacing national markets in Europe and the U.S., but major drugmakers have been slow to expand in these markets and may lose opportunities, a new study finds, The New York Times reports. To put the shift in perspective, China will overtake both France and Germany next year in terms of drug spending, while Brazil will overtake Britain, according to the report by research firm IMS Health.

18 Mar 2010

Cangene receives European Commission approval to market ImmunoGam

Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.

18 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Tel Aviv, Israel.

17 Mar 2010

MiddleBrook Pharmaceuticals, DoctorDirectory.com enter into agreement to expand IncreaseRx promotion program

MiddleBrook Pharmaceuticals, Inc. today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner for MOXATAG (amoxicillin extended-release) Tablets, 775 mg, to expand its previously announced IncreaseRx® promotion program.

17 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost.

17 Mar 2010

In-depth analysis of Asia-Pacific drug development landscape

As drug makers around the world continue to navigate the complex and ever-changing landscape referred to as the New Health, many companies are flocking to Asia-Pacific for better access to patients, improved operational efficiencies and increasingly, pharmaceutical innovation.

17 Mar 2010

Pharmaceutical News

Having lower TSH levels while taking thyroxine replacement is not detrimental to health, says study

NexACT technology demonstrates ability to deliver Taxol subcutaneously

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Acurox NDA: FDA schedules Advisory Committee meeting

Nature News examines GAVI Alliance's budget gap

New specialty service at Montefiore Medical Center helps patients with drug allergies

Actavis receives FDA marketing approval for Alprazolam ODT

Hypnotherapy and probiotics effective for reducing IBS symptoms

NICE leaves many patients with rarer forms of cancer without drugs

High plasma selenium concentrations linked to lower occurrence of dysglycemia in elderly men

Purified form of omega 3 curbs precancerous bowel polyps

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Drugmakers are 'under-exposed' in emerging markets, report says

Cangene receives European Commission approval to market ImmunoGam

AstraZeneca's CRESTOR: Health Canada approves new indication

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

MiddleBrook Pharmaceuticals, DoctorDirectory.com enter into agreement to expand IncreaseRx promotion program

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

In-depth analysis of Asia-Pacific drug development landscape

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News